Company & Sponsor Intelligence
Novartis Pharmaceuticals
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials11
Recruiting2
Completed7
Countries5
Therapeutic footprint
adhdalzheimersdepressionepilepsymultiple_sclerosisneuromuscularother_neurology
Indexed studies
NCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
alzheimers · United StatesPHASE2, PHASE3
alzheimers · United StatesPHASE2, PHASE3
NCT06251986A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
multiple_sclerosis · SpainCOMPLETED
multiple_sclerosis · SpainCOMPLETED
NCT03096834A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
epilepsy · AustraliaPHASE3
epilepsy · AustraliaPHASE3
NCT00776009Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT01137682Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
other_neurology · United StatesPHASE3
other_neurology · United StatesPHASE3
NCT01156415Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)
depression · United StatesPHASE3
depression · United StatesPHASE3
NCT01585272Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
alzheimers · TaiwanPHASE4
alzheimers · TaiwanPHASE4
NCT06869785Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
multiple_sclerosis · United StatesPHASE3
multiple_sclerosis · United StatesPHASE3
NCT02576639Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
NCT06744920A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
neuromuscular · United StatesPHASE3
neuromuscular · United StatesPHASE3
NCT01047579A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease
alzheimers · IsraelPHASE4
alzheimers · IsraelPHASE4
Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →